INTRODUCTION
Human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS) are important health concerns worldwide; however, antiretroviral therapy (ART) has significantly decreased the mortality rate and the incidence of opportunistic infections and improved the quality of life of HIV patients (1) (2) (3) (4) . HIV viral load (HIV RNA) and CD4 ＋ cell count are used as markers to determine responsiveness to therapy in which HIV RNA declines to an undetectable level within 6 months (5), and the CD4 ＋ cell count gradually increases by an average of 50-150 cells/mm 3 /year (6,7) until nearly normal levels are reached and patients achieve good immunological responses. CD4 ＋ T cells are essential lymphocytes for prevention of opportunistic infection and progression to AIDS and also enhance survival in HIV-infected patients (8, 9) . Opportunistic infections and mortality are significantly decreased in HIV-infected patients who have a CD4 ＋ cell count À 200 cells/mm 3 (10) (11) (12) . In HIV-infected patients who receive ART and achieve complete viral suppression (undetectable HIV RNA), a discordant rise of CD4 ＋ cell count is known as immunological discordance, which is associated with a higher risk of mortality and disease progression (13, 14) . Immunological discordance has been reported in 15-30z of patients who receive ART (15) , and the risk factors for this condition are advanced age, low nadir CD4 ＋ cell count, hepatitis C virus (HCV) coinfection, and poor adherence to ART (15) (16) (17) (18) . There are several controlled studies regarding immunological responses in HIV patients using interleukin (IL)-2 and IL-7, some of which have demonstrated the effectiveness of immunotherapy (19, 20) . However, the benefits of immunotherapy remain unclear, and the United States Department of Health and Human Service guidelines have recommended that immune-based therapies should not be used unless in the context of clinical research (21) .
Baum et al. recently reported a benefit of zinc supplementation without adverse effects to prevent immunological failure in HIV-infected patients with low plasma zinc levels (22) . Zinc is an essential micronutrient for the immune system, particularly for the regeneration of new CD4 ＋ T cells and maintenance of T cytolytic cell concentrations (23) . Zinc deficiency may result in a reduction of T cell generation and impairment of cell-mediated and humoral immune responses (22) . Several studies have reported that up to 50z of HIV-infected patients have low plasma zinc levels and inadequate zinc intake (24, 25) . Subsequent rapid HIV disease progression and increased mortality were found in this group of patients (26) . Zinc supplementation in HIV-infected patients has been conducted in some stu-dies that have shown benefits in delayed disease progression, decreased incidence of opportunistic infections, and reduced HIV-related mortality (22, (27) (28) (29) (30) . However, the benefits of zinc supplementation in patients with immunological discordance and low plasma zinc levels are yet to be addressed. Thus, herein we assessed plasma zinc levels and immunological responses to zinc supplementation in HIV-infected patients with immunological discordance.
METHODS
We designed a pilot clinical study of two phases; phase one was a cross-sectional study to determine plasma zinc levels, and phase two was a prospective, randomized, placebo-controlled clinical trial to determine the effects of zinc supplementation on the rising CD4 ＋ cell counts in HIV-infected patients with immunological discordance in a medical school in Bangkok, Thailand. Eligibility criteria were as follows: (i) age AE18 years, (ii) documented HIV infection, (iii) recipient of ART for at least 12 months, (iv) with complete viral suppression (HIV RNA º 40 copies/mL), and (v) having CD4 ＋ cell count º 200 cells/mm 3 that increased º30z from baseline after achieving undetectable HIV RNA after 12 months of ART. Women who were pregnant or planning to become pregnant and patients who previously received zinc supplementation were excluded from the study. The study was approved by the institutional ethics committee.
According to the criteria established in previous study (15) , an HIV-infected patient with immunological discordance was defined as a patient who received ART, had complete virological responses with HIV RNA º 40 copies/mL, and had inadequate immunological responses with a CD4 ＋ cell count º 200 cells/mm 3 that increased º30z from baseline after undetectable HIV RNA for 12 months. Plasma zinc levels in each participant were measured to estimate the prevalence of low plasma zinc levels, which was defined as º75 mg/dL. Patients were subsequently stratified into two groups (low and normal plasma zinc levels) and randomized to receive zinc supplementation or a placebo in a 1:1 ratio by blocks of four in a particular group. Daily zinc supplementation consisted of 15 mg of chelated zinc, which is a nutritional dose that has been found to be safe for use in HIV-infected patients (22) . Our pharmacy bottled 90 zinc or placebo pills for the study, which were indistinguishable in shape, size, and color. The bottles were dispensed to each participant every 3 months, and the remaining pills were counted to assess adherence.
Data regarding demographics, coinfection with hepatitis B virus (HBV) or HCV, previous opportunistic infections, and past and current ART regimens were collected at enrollment. Monitoring of clinical condition, adherence, and adverse effects was performed every 3 months. Plasma zinc levels, complete blood counts, CD4 ＋ cell counts, HIV RNA, and levels of alanine aminotransferase, creatinine, fasting blood glucose, total cholesterol, triglyceride, and C-reactive protein were assayed every 6 months. Adherence to the assigned regimen was determined by counting the number of pills returned.
Plasma zinc levels were measured by atomic absorption spectrophotometry. Lymphocyte phenotype was determined using a tricolor immunophenotyping panel of monoclonal antibodies. HIV viral loads were determined using an in vitro nucleic acid amplification test (Amplicor reagents and protocol; Roche-Diagnostics, Mannheim, Germany). The primary outcomes of this study were plasma zinc levels and the number of patients who had low plasma zinc levels at baseline. The secondary outcomes were median changes in plasma zinc levels and CD4 ＋ cell counts after 6 months of zinc supplementation.
Intent-to-treat analysis was performed. A calculated sample size for 80z power of detection with a 95z twosided confidence level and an estimated 20z of exposure with outcome indicated 154 participants with a 1:1 zinc supplementation and placebo ratio. However, due to the rarity of cases and a limited budget, we planned to conduct an initial pilot study to test our concept. We were able to enroll 31 patients with immunological discordance from an HIV clinic in a medical school hospital between May 2011 and April 2012.
Patient characteristics were presented by means ± SD for continuous variables with normal distribution and median and interquartile range (IQR) for continuous variables with non-normal distribution. The Student's t test and Mann-Whitney U test were used to compare continuous variables between groups. Frequency and proportion were used to describe categorical variables and comparisons between groups were assessed using chi-square test and Fisher's exact test where appropriate. The paired t-test and Wilcoxon signedrank test were used to determine the effect of zinc supplementation on plasma zinc levels and CD4 ＋ cell counts. A two-sided P value of º0.05 was considered statistically significant. All statistical analyses were performed using SPSS version 16.
RESULTS
Of 31 HIV-infected patients with immunological discordance, the median (IQR) plasma zinc level was 76 (range, 66-88) mg/dL. Twelve (39z) patients had low plasma zinc levels with a median (IQR) zinc level of 65 (range, 57-69) mg/dL, and the lowest plasma zinc level was 51 mg/dL. Among 19 patients with normal plasma zinc levels, the median (IQR) zinc level was 85 (range, 79-103) mg/dL. The patient characteristics are shown in Table 1 . The mean patient age was 45 ± 11 years, and males constituted 68z of the study population. Comparisons between patients with low and normal plasma zinc levels, age, gender, body weight, and body mass index (BMI) were similar between the two groups. The median baseline CD4 ＋ cell count in patients with normal plasma zinc levels was slightly higher than that in patients with low plasma zinc levels, but there was no statistically significant difference.
A history of opportunistic infections was found in 52z of patients with tuberculosis as the most common. Other opportunistic infections are described in Table 1 . Frequencies of HBV or HCV coinfections were not different between patients with low and normal plasma zinc levels. Twenty-six (83z) patients concurrently used cotrimoxazole as a prophylaxis for Pneumocystis pneumonia, which was similar between patients with low and normal plasma zinc levels. All of the patients received non-nucleoside reverse transcriptase inhibitor-based regimens. The distribution of ART regimens was similar between the two groups ( Table 1) . None of the study participants died or was hospitalized during the study period. One patient experienced an adverse reaction from zinc supplementation and presented with erythematous rashes on the body trunk after receiving zinc supplementation for 1 month, but the rashes resolved when zinc supplementation was discontinued.
Of 12 patients with low plasma zinc levels, 5 were randomized to receive zinc supplementation and 7 received a placebo. Of 19 patients with normal plasma zinc levels, 8 were randomized to receive zinc supplementation and 11 received a placebo (Fig. 1) . Table 2 shows plasma zinc levels at baseline and after supplementations in all groups. Median changes in plasma zinc levels after zinc supplementation versus placebo in patients with low plasma zinc level were 29 mg/dL versus 4.5 mg/dL, respectively. The details of plasma zinc levels at baseline and after supplementation in each patient with low and normal plasma zinc levels are shown in Figs. 2 and 3 , respectively. Plasma zinc levels were higher after zinc supplementation, particularly in patients with low plasma zinc levels at baseline (Fig. 2) . Median changes in plasma zinc levels after zinc supplementation versus placebo in patients with normal plasma zinc level were -8 mg/dL versus -4 mg/dL, respectively. Fig. 2 . Plasma zinc level responses to supplementation with zinc (solid line) or placebo (dot line) in patients with low plasma zinc level. Fig. 3 . Plasma zinc level responses to supplementation with zinc (solid line) or placebo (dot line) in patients with normal plasma zinc level.
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In the group of patients with low plasma zinc levels, the median (IQR) CD4 Table 2 ). In addition, the percentage of patients who had CD4 ＋ cell count increased by À30z after supplementation was also higher in patients receiving zinc supplementation (60z versus 29z, P ＝ 0.025; Table 2 ). In the group of patients with normal plasma zinc levels, the median CD4 ＋ cell counts after supplementation were not significantly different from baseline in patients who received zinc or the placebo ( P À 0.05).
DISCUSSION
The first phase of this pilot study (a cross-sectional study of plasma zinc level in HIV-infected patients with immunological discordance) found that 39z of patients had low plasma zinc levels. To date, the present study is the first to determine the zinc status in HIV-infected patients with immunological discordance. The second phase (a randomized, placebo-controlled trail of zinc supplementation administered to HIV-infected patients who have immunological discordance) showed increased plasma zinc levels and significantly increased CD4 ＋ cell counts after zinc supplementation in patients with low plasma zinc levels. Regarding adverse side effects, one patient developed minor rashes that resolved after discontinuation of the drug. None of the patients died or were hospitalized for any cause during the study period.
Zinc deficiency and low plasma zinc levels in HIVinfected patients have been previously reported with a prevalence ranging from 3z to 96z, depending on the characteristics of the study population, such as stage of HIV disease and nutritional status (31) and the criteria for zinc deficiency varied from º55 mg/dL to º75 mg/dL (24). We defined low plasma zinc level as º75 mg/dL according to previous studies by Baum et al., which demonstrated that such criteria was related to clinical outcomes (22, 25, 30) . From a recent study with a low plasma zinc level defined as º75 mg/dL, the prevalence of low plasma zinc levels was 56z in HIV-infected patients with a history of intravenous drug use (30). The mean plasma zinc level in this previous study was 73 mg/dL, which was in accordance with the results from the present study (76 mg/dL). In contrast to the previous studies (30-32), we found no association between plasma zinc level and BMI or CD4 ＋ cell count. In addition, the plasma zinc levels in the present study were also comparable with that in an HIV-uninfected Thai population (33) .
Zinc supplementation generally has a good safety profile, particularly at a nutritional dosage (22, 31) . However, one patient developed an erythematous rash and itching after zinc supplementation for 1 month. Although this adverse effect was mild, such an event should be considered prior to prescribing zinc supplementation for HIV patients. A recent meta-analysis of available studies found that zinc supplementation produced a statistically significant increase in plasma zinc concentrations and provided an estimate of the dose-response relationship between zinc supplementation and plasma zinc concentrations (34) . A kinetic model of zinc metabolism in humans showed that approximately 37z of ingested zinc enters the circulation. Gastrointestinal absorption is essentially completed within 4 h (35). The absorption of zinc occurs slowly, but humans have a capacity to cope with large fluctuations in zinc intake. Plasma zinc balance is usually achieved after zinc intake for 6-12 days (36) .
The present pilot study has some limitations; the small sample size and short-term supplementation are the most important limitations. Six months of zinc supplementation in the present study may be too short a duration to determine the small and gradual effects of micronutrients. To correct unobvious effects, a larger sample size should be used in the study. In this pilot study, the number of patients was only 20z of the calculated sample size.
A future large-scaled double blind, placebo-controlled, randomization trial to better determine the effectiveness of zinc supplementation to reconstitute immune response in HIV-infected patients with immunological discordance should be conducted with longer duration of supplementation. A multicenter collaboration may solve the problem of the rarity of study population. For practitioners who treat HIV-infected patients with immunological discordance receiving HAART, we propose that zinc supplementation should be considered for patients with low plasma zinc levels. Plasma zinc levels and CD4 ＋ cell counts should be regularly monitored to evaluate the effectiveness of zinc supplementation.
In conclusion, low plasma zinc levels are observed in more than one-third of HIV-infected patients with immunological discordance. This pilot study demonstrated that zinc supplementation for 6 months can increase the plasma zinc levels and significantly increase CD4 ＋ cell counts. However, clinicians should be aware that zinc supplementation may cause minor skin irritations. Given the limitation of the sample size and short duration of zinc supplementation, further large-scale studies to determine long-term benefit of zinc supplementation in patients with immunological discordance are required.
